Therapeutic use of interferon-α for lymphomatoid papulosis
✍ Scribed by Matthias Schmuth; Gerda Topar; Brigitte Illersperger; Elisabeth Kowald; Peter O. Fritsch; Norbert T. Sepp
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 624 KB
- Volume
- 89
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
nodes decreased in size and became impalpable. After discharge in February 1989, he was treated with maintenance chemotherapy every 3 months for 2 1 ⁄2 years. In October 1992, he had lt-inguinal lymph-node swelling and lymphocytosis. His leukocyte count was 10,000/l (neutrophils 23%, lymphocytes 72%
nodes decreased in size and became impalpable. After discharge in February 1989, he was treated with maintenance chemotherapy every 3 months for 2 1 ⁄2 years. In October 1992, he had lt-inguinal lymph-node swelling and lymphocytosis. His leukocyte count was 10,000/l (neutrophils 23%, lymphocytes 72%
After immunoafflnity chromatography, interferon x-2a synthesized in bacteria is not homogeneous. Beside oligomers and monomers: a fragment of molecular weight 15 000 was observed. Amino acid analysis and the determination of the amino terminal amino acid sequence of the fragment indicate that this